ALLENA PHARMACEUTICALS INC (ALNA) Stock Price, Forecast & Analysis
NASDAQ:ALNA • US0181191075
ALNA Key Statistics, Chart & Performance
The current stock price of ALNA is 0.075 USD. In the past month the price decreased by -41.36%. In the past year, price decreased by -92.72%.
ALNA Technical Analysis
ALNA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALNA. ALNA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALNA Financial Highlights
Over the last trailing twelve months ALNA reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 46.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -243.13% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALNA Forecast & Estimates
7 analysts have analysed ALNA and the average price target is 4.08 USD. This implies a price increase of 5340% is expected in the next year compared to the current price of 0.075.
ALNA Ownership
ALNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALNA
Company Profile
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Sudbury, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2017-11-02. The firm is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The firm is conducting two Phase IIa studies for ALLN-346.
Company Info
ALLENA PHARMACEUTICALS INC
142 -F North Road, Suite 150
Sudbury MASSACHUSETTS 02462 US
CEO: Louis Brenner
Employees: 21
Phone: 16174674577.0
ALLENA PHARMACEUTICALS INC / ALNA FAQ
What does ALLENA PHARMACEUTICALS INC do?
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Sudbury, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2017-11-02. The firm is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The firm is conducting two Phase IIa studies for ALLN-346.
What is the current price of ALNA stock?
The current stock price of ALNA is 0.075 USD. The price increased by 3.16% in the last trading session.
Does ALNA stock pay dividends?
ALNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALNA stock?
ALNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about ALLENA PHARMACEUTICALS INC (ALNA) stock?
7 analysts have analysed ALNA and the average price target is 4.08 USD. This implies a price increase of 5340% is expected in the next year compared to the current price of 0.075.
What is ALLENA PHARMACEUTICALS INC worth?
ALLENA PHARMACEUTICALS INC (ALNA) has a market capitalization of 8.08M USD. This makes ALNA a Nano Cap stock.